Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2019 Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2700 West Front Street Statesville, North Carolina 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: 704-873-7202 N/A (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $2.50 par value KEQU NASDAQ Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. (a) and (b) On August 28, 2019, the Company held its 2019 Annual Meeting of Stockholders. At that meeting, the Company’s shareholders voted on the matters set forth below. 1. Each of the nominees named below was re-elected as a Class III director for a three year term as follows: Name of Nominee For Withheld Non-Votes Margaret B. Pyle 1,707,220 179,091 584,539 Donald F. Shaw 1,726,548 159,763 584,539 2. The independent registered public accounting firm of Ernst & Young LLP was ratified as the Company’s independent auditor for fiscal year 2020 as follows: For Against Abstained 2,445,411 16,375 9,093 3. The compensation of the Company’s named executive officers was approved on an advisory basis pursuant to the following votes: For Against Abstained Non-Votes 1,688,434 142,704 55,202 584,539 4. An advisory vote on whether the frequency of holding an advisory vote on executive compensation should be every one year, two years or three years resulted in the following votes: One Year Two Years Three Years Abstained Non-Votes 1,493,036 47,103 256,676 89,525 584,539 (d) In accordance with the recommendation of the Board of Directors and consistent with the vote of the Company’s stockholders, the Company will include an advisory non-binding vote of the Company’s stockholders on the compensation of the Company’s named executive officers in its proxy materials on an annual basis. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Registrant) Kewaunee Scientific Corporation Date: August 30, 2019 /s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance and Chief Financial Officer 3